UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    14

    A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

    Read More

    Oct

    15

    Powering the dreams of people impacted by myasthenia gravis (MG)

    Read More

    Oct

    15

    UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia gravis in the U.S.

    Read More

    Oct

    14

    UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (bimekizumab-bkzx)

    Read More

    Oct

    11

    UCB showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

    Read More

    Sep

    30

    UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

    Read More

    Sep

    25

    UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

    Read More

    Sep

    23

    UCB Announces U.S. FDA Approvals for BIMZELX® (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

    Read More

    Sep

    23

    Redefining Immunology Care: Our Pledge to Patients and the Healthcare Community

    Read More

    Sep

    09

    TK2d Awareness Day: The complexity of this rare, genetic mitochondrial disease and its impact on daily living can no longer be overlooked

    Read More